AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Cong...
May 17 2018 - 7:00AM
Business Wire
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE
American: BTX), today announced that the company’s Chief Executive
Officer Michael D. West, Ph.D., who also serves as Co-CEO of
BioTime, will deliver a keynote presentation at World Advanced
Therapies & Regenerative Medicine Congress, May 16-18 in
London.
Taking place on Friday, May 18 at 12:30pm BST, Dr. West’s
presentation, “Aging and Regeneration: Commercial Implications of
the New Science” will address the following topics related to
AgeX’s programs:
- How can molecular and AI technologies
help regenerate damaged tissue in humans?
- What are the current challenges with
induced tissue regeneration and how are we tackling them?
- Combining pluripotent stem cell and iTR
technology to form new company AgeX
A copy of Dr. West’s presentation will be available on the AgeX
website.
About AgeX Therapeutics
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE
American: BTX), is a biotechnology company applying technology
relating to cellular immortality and regenerative biology to aging
and age-related diseases. The company has three initial areas of
product development: pluripotent stem cell-derived brown adipocytes
(AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue
Regeneration (iTR). Initial planned indications for these products
are Type 2 diabetes, cardiac ischemia, and tissue regeneration
respectively. For more information, please visit www.agexinc.com or
connect with the company on Twitter, Facebook and YouTube.
About BioTime
BioTime is a clinical-stage biotechnology company focused on
degenerative diseases. Its clinical programs are based on two
platform technologies: cell replacement and cell/drug delivery.
With its cell replacement platform, BioTime is creating new cells
and tissues with its proprietary pluripotent cell technologies.
These cells and tissues are developed to replace those that are
either rendered dysfunctional or lost due to degenerative diseases.
BioTime’s cell/drug delivery programs are based upon its
proprietary HyStem® cell and drug delivery matrix technology.
HyStem® was designed to provide for the transfer, retention,
engraftment and metabolic support of cellular replacement
therapies. BioTime’s lead cell delivery clinical program is
Renevia®, which consists of HyStem® combined with the patient's own
adipose (fat) progenitor cells. Renevia® met its primary endpoint
in an EU pivotal clinical trial for the treatment of facial
lipoatrophy in HIV patients in 2017. BioTime has submitted Renevia®
for CE Mark approval in the EU. There were no device related
serious adverse events reported to date. BioTime’s lead cell
replacement product candidate is OpRegen®, a retinal pigment
epithelium transplant therapy, which is in a Phase I/IIa
multicenter clinical trial for the treatment of dry age-related
macular degeneration, the leading cause of blindness in developing
countries. There were no related serious adverse events reported to
date in the first nine patients. BioTime also has significant
equity holdings in two publicly traded companies, Asterias
Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation
(NYSE American: OCX), and a private company, AgeX Therapeutics,
Inc.
BioTime common stock is traded on the NYSE American and
TASE under the symbol BTX. For more information, please
visit www.biotime.com or connect with the company
on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
To receive ongoing BioTime corporate communications, please
click on the following link to join the Company’s email alert list:
BioTime News Alerts.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Statements pertaining to
product technology, clinical development, regulatory approval
timelines, the success of potential cosmetic applications and
potential opportunities for BioTime, Inc. and its
subsidiaries, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates” should also be considered
forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business
of BioTime, Inc. and its subsidiaries, particularly those
mentioned in the cautionary statements found in more detail in the
“Risk Factors” section of its Annual Reports on Form 10-K and
Quarterly Reports on Form 10-Q filed with the SEC (copies
of which may be obtained at www.sec.gov). Subsequent events
and developments may cause these forward-looking statements to
change. BioTime specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date
of this release, except as required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180517005414/en/
Investor Contact for BioTime:David Nakasone,
510-871-4188Dnakasone@biotime.comorMedia Contact for AgeX:Gotham
Communications, LLCBill Douglass,
646-504-0890bill@gothamcomm.comorNext Level Agency, Inc.Mark
Leonard, 847-651-9682mark@reachthenextlevel.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024